(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The pace of hiring just fell to the lowest since 2011, outside of the pandemic - 2Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- 3An Aide On Upgrading Your FICO rating
- 4You finally got a doctor's appointment. Here's how to get the most out of it
- 5Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- No injuries after blast at pro-Israel centre in the Netherlands
- Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- Benedict Cumberbatch takes on something even Sherlock can’t solve: male grief
- How effective is the flu shot this year? New report shows promising results
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- Alleged maple syrup scam in Quebec uncovered by Canadian broadcaster
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- James Webb Space telescope spots 'big red dot' in the ancient universe: A ravenous supermassive black hole named 'BiRD'
- New York to require social media platforms to display mental health warnings
